ArticleJAMA2006
Use of nesiritide before and after publications suggesting drug-related risks in patients with acute decompensated heart failure.
Article in JAMA, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 61 citations in OpenAlex.
- Observational
- Current Understanding of the Compensatory Actions of Cardiac Natriuretic Peptides in Cardiac Failure: A Clinical Perspective.Cardiac failure review · 2016Article
- Towards understanding the de-adoption of low-value clinical practices: a scoping review.BMC medicine · 2015Article
- Understanding mis-implementation in public health practice.American journal of preventive medicine · 2015Article
- Oncologists' response to new data regarding the use of epidermal growth factor receptor inhibitors in colorectal cancer.Journal of oncology practice · 2014Observational
- Patterns of change in nesiritide use in patients with heart failure: how hospitals react to new information.JACC. Heart failure · 2013Article
- Natriuretic Peptide system and cardiovascular disease.Heart views : the official journal of the Gulf Heart Association · 2010Article
- The role of natriuretic peptides in heart failure.Current heart failure reports · 2008Article
- Effect of regulatory warnings on antipsychotic prescription rates among elderly patients with dementia: a population-based time-series analysis.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2008Article
- Concerns about health care warnings and their impact on prescribing behaviour.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2008Review
- Short-term mortality and cost associated with cardiac device implantation in patients hospitalized with heart failure.American heart journal · 2008Article
- Insights into natriuretic peptides in heart failure: an update.Current heart failure reports · 2008Review
- The role of natriuretic peptides in heart failure.Current cardiology reports · 2008Review
- The tumultuous journey of nesiritide: past, present, and future.Circulation. Heart failure · 2008Article
- Nesiritide in acute decompensated heart failure: current status and future perspectives.Reviews in cardiovascular medicine · 2008Review
- Safety and efficacy of nesiritide for acute decompensated heart failure: recent literature and upcoming trials.Current cardiology reports · 2007Review
- Nesiritide for acute decompensated heart failure: does the benefit justify the risk?Current cardiology reports · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
contextThe rate of adoption of new therapies for cardiovascular diseases following the publication of favorable clinical trial results has been studied; however, less is known about the rates of de-adoption of a drug when negative studies are published.
objectiveTo evaluate the use of nesiritide before and after March and April 2005 publications in 2 high-impact journals that suggested an increased risk of renal failure and mortality with intravenous nesiritide for acute decompensated heart failure. DESIGN, SETTING, AND PATIENTS: Analysis of a large prospective hospital database, developed for quality and utilization benchmarking, of 491 acute care US hospitals at which 385,627 inpatient admissions occurred with a primary International Classification of Diseases, Ninth Revision (ICD-9) code for heart failure between January and August 2001 (prior to nesiritide release) and January 2004 to December 2005 (before and after publication periods). In addition, any patient admitted who received nesiritide in the absence of a primary or secondary heart failure code was evaluated for potential off-label use of the drug.
main outcome measureUse of nesiritide and other intravenous vasoactive therapy among patients admitted with heart failure.
resultsNesiritide use decreased from a peak of 16.6% (2351 of 14,167 admissions) in March 2005 to 5.6% (611 of 10,822 admissions) in December 2005 (P<.001). Among those patients treated with nesiritide, the mean duration of treatment changed minimally, from 2.3 to 2.1 days. Although the use of inotropes also decreased during the period under study, the changes were more modest; furthermore, of those patients who were prescribed intravenous vasoactive therapy, a higher percentage were prescribed inotropes after publication (3272 [21.5%] of 15 193 patients from January-April 2005 vs 5750 [29.6%] of 19 445 patients from May-December 2005, P<.001). The use of nesiritide, in the absence of an ICD-9 heart failure code, was small.
conclusionsRapid de-adoption of nesiritide occurred following 2 publications suggesting risk with the drug. Further analyses are required to evaluate the consequences of these changes on patient outcomes and to anticipate how publications of adverse findings can influence practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.